3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
15
Leukemia, Lymphocytic, Chronic, B-Cell
11
Burkitt Lymphoma
10
Lymphoma
9
Leukemia
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Follicular
8
Lymphoma, Non-Hodgkin
7
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Myelodysplastic Syndromes
6
Multiple Myeloma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Myeloproliferative Disorders
5
Lymphoma, Large B-Cell, Diffuse
5
Hodgkin Disease
5
Lymphoma, Large-Cell, Immunoblastic
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Hematologic Neoplasms
4
Congenital Abnormalities
4
Sezary Syndrome
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Biphenotypic, Acute
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Primary Myelofibrosis
2
Neoplasms, Plasma Cell
2
Interventions
Paclitaxel
6
Radiotherapy
5
Carboplatin
5
capmatinib
2
Radiosurgery
2
Gemcitabine
2
tetrathiomolybdate
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
onartuzumab
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
efaproxiral
1
durvalumab
1
binimetinib
1
aldesleukin
1
Vinorelbine
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sorafenib
1
Platinum
1
Nivolumab
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gefitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma of Lung
×
fludarabine phosphate
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn